The PEACOCC trial showed clinical benefit with pembrolizumab in patients with previously treated advanced clear cell gynae cancer, of whom all except 1 had mismatch repair-proficient disease. ja.ma/40NlBjB

Do clinicians and patients see the same picture? In adjuvant BC therapy trials, agreement on side effects is weak. Patient-reported outcomes (#PROs) show symptoms that doctors often don't see. Both views are vital for patient-centred care. #ESMOBreast25

New drugs @ASCO2025 Gustave Roussy

Great presentation on how to use tarlatamab and TCEs in clinical practice in solid tumors. #ASCO25

BLB01D1 HER2/EGFR ADC with TOPO1 payload in NSCLC with genomic drivers. 67% received 1 prior line of tt -> ORR 46.2%, PFS 7 mths -> ORR greater in non classical EGFRm -> Most seen G3+ AE was hem tox (neutropenia++) #ASCO25

HER3/EGFR bispecific TOPO1 ADC BL-B01D1 showed a 75% ORR in pts with SCLC pre treated with 1 line, -> mPFS 6.9m, mOS 12m -> 74% G3+ TRAEs (hem tox) , no ILD #ASCO25

Wonderful presentation on KRAS G12Ci + cetuximab in CRC by HollebecqueA #ASCO25 ! 👉43% ORR; overall good safety profile

🔹 Gustave Roussy at #ASCO25 🔹 Dr. Antoine Hollebecque, oncologist at Gustave Roussy, presents a new combination of treatments for patients with colorectal #cancer in treatment failure at ASCO. Press release ➡ ow.ly/Ye0r50W1Z0X

The approval of afamitresgene autoleucel (afami-cel), a TCR therapy for HLA-A*02 and MAGE-A4-expressing synovial sarcoma, highlights the potential for further development of TCR-based therapies in solid tumors. PRAME is another important target for TCR therapy. #ASCO25

mRNA bispecific CD3/CLDN6 BNT142 showed promising preliminary activity in heavily pretreated OC pts -> ORR 17% -> 21% CRS mostly low grade; -> 12% of pts experienced G3+ LFT elevation #ASCO25

NP-G2-004 -> new drug targeting Fascin Combo with anti-PD1 in advanced solid tumors resistant to PD(L)1 therapy 👉 27% ORR, 76% DCR in multiple solid tumors (cervix, endometrial, pancreatic..) with durable response up to 19m 👉 11% LFT elevation associated w response #ASCO25

Ph1 SIRP1 inh BI 770371 +/- anti PD1 in solid tumors (> 80% received 2+ prior lines) 👉 No response but some pts presented prolonged SD in mono and combo 👉 Most frequent G3 TRAE fatigue and diarrhea #asco

🌟🔵 Promising data in mCRPC: Pasritamig (KLK2xCD3) #ASCO25 First-in-human phase 1 study of JNJ-78278343 Presented by Dr. Capucine Baldini OncoAlert 🔵 Novel KLK2 target: prostate-specific expression 🔵 PSA50 in 42.4% of pts at RP2D (IV Q6W) 🔵 rPFS: 6.8 mo | ORR: 16.1% in

🔹 Capucine Baldini, DITEP at Gustave Roussy, presenting pasritamig, a first in human, first in class, bispecific T-cell engager targeting Kallikrein 2 (KLK2-CD3) in CRPC - a potential game changer ! Simultaneous publication in J Clin Oncol. ASCO #ASCO

Presented at #ASCO25: Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. Full DeLLphi-304

🙌ROSELLA ! Overall survival benefit (👍PFS benefit too) with the addition of relacorilant (glucocorticoid antagonist) to nab-paclitaxel in platinum resistant #ovariancancer 🎉🔥Another big win for our patients!!! #ASCO25 #gyncsm

📰 Moins d’un an après son lancement, le parcours FRESH étend l’accès à la médecine de précision sur tout le territoire, métropolitain et ultramarin. Lire le communiqué de presse ➡ gustaveroussy.fr/fr/moins-dun-a…

New #JITC article: ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy bit.ly/4eVYBpa